Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-08-07 Sale |
2024-08-09 4:30 pm |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Invus Public Equities Advisors LLC Siren L.L.C. Invus Global Management LLC DEBBANE RAYMOND 10% Owner |
322,361 | $0.18987 | $61,206 | 6,317,565 (Direct) |
View |
| 2024-08-05 Sale |
2024-08-07 4:30 pm |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Invus Public Equities Advisors LLC Siren L.L.C. Invus Global Management LLC DEBBANE RAYMOND 10% Owner |
220,255 | $0.18698 | $41,184 | 6,639,926 (Direct) |
View |
| 2024-08-01 Sale |
2024-08-05 4:53 pm |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Invus Public Equities Advisors LLC Siren L.L.C. Invus Global Management LLC DEBBANE RAYMOND 10% Owner |
349,764 | $0.20327 | $71,097 | 6,860,181 (Direct) |
View |
| 2024-07-26 Sale |
2024-07-30 5:16 pm |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Invus Public Equities Advisors LLC Siren L.L.C. Invus Global Management LLC DEBBANE RAYMOND 10% Owner |
1,379,119 | $0.2286 | $315,262 | 7,209,945 (Direct) |
View |
| 2024-06-20 Purchase |
2024-06-24 4:29 pm |
GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer |
305,000 | $0.25844 | $78,825 | 680,403 (Direct) |
View |
| 2024-06-18 Purchase |
2024-06-20 4:15 pm |
GLYCOMIMETICS INC | GLYC | Hahn Brian M. SVP Finance, CFO |
17,500 | $0.2477 | $4,335 | 70,643 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-07-16 Option Award |
2025-07-16 7:11 pm |
N/A 2035-07-16 |
CRESCENT BIOPHARMA INC. | CBIO | Pinkas Jan Chief Scientific Officer |
142,474 | $0 | 142,474 (Direct) |
View |
Ownership |
2025-06-30 4:21 pm |
N/A 2035-04-01 |
CRESCENT BIOPHARMA INC. | CBIO | Im Ellie Eunkyung Chief Medical Officer |
0 | $0 | 257,822 (Direct) |
View |
Ownership |
2025-06-30 4:16 pm |
N/A 2035-01-13 |
CRESCENT BIOPHARMA INC. | CBIO | Bispham Barbara Harlin See Remarks |
0 | $0 | 106,235 (Direct) |
View |
| 2025-06-23 Option Award |
2025-06-23 6:51 pm |
N/A 2035-06-23 |
GLYCOMIMETICS INC | CBIO | Moran Susan Director |
9,023 | $0 | 9,023 (Direct) |
View |
| 2025-06-23 Option Award |
2025-06-23 6:48 pm |
N/A 2035-06-23 |
GLYCOMIMETICS INC | CBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner |
9,023 | $0 | 9,023 (Indirect) |
View |
| 2025-06-23 Option Award |
2025-06-23 6:46 pm |
N/A 2035-06-23 |
GLYCOMIMETICS INC | CBIO | Violin Jonathan Director |
9,023 | $0 | 9,023 (Direct) |
View |
| 2025-06-23 Option Award |
2025-06-23 6:43 pm |
N/A 2035-06-23 |
GLYCOMIMETICS INC | CBIO | Balcom Alexandra Director |
9,023 | $0 | 9,023 (Direct) |
View |
| 2025-06-23 Option Award |
2025-06-23 6:41 pm |
N/A 2035-06-23 |
GLYCOMIMETICS INC | CBIO | Lubner David Charles Director |
9,023 | $0 | 9,023 (Direct) |
View |
Ownership |
2025-06-23 6:29 pm |
N/A 2034-12-27 |
GLYCOMIMETICS INC | CBIO | Lynch Ryan See Remarks |
0 | $0 | 105,706 (Direct) |
View |
Ownership |
2025-06-23 6:29 pm |
N/A N/A |
GLYCOMIMETICS INC | CBIO | Doughty Christopher Grant Chief Business Officer |
0 | $0 | 192,262 (Direct) |
View |
Ownership |
2025-06-23 6:28 pm |
N/A 2035-04-01 |
GLYCOMIMETICS INC | CBIO | Scalzo Richard William Chief Financial Officer |
0 | $0 | 234,383 (Direct) |
View |
Ownership |
2025-06-23 6:27 pm |
N/A N/A |
GLYCOMIMETICS INC | CBIO | McNeill Jonathan See Remarks |
0 | $0 | 536,800 (Direct) |
View |
Ownership |
2025-06-23 6:26 pm |
N/A N/A |
GLYCOMIMETICS INC | CBIO | Brumm Joshua T Chief Executive Officer |
0 | $0 | 1,073,600 (Direct) |
View |
Ownership |
2025-06-23 6:25 pm |
N/A N/A |
GLYCOMIMETICS INC | CBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner |
0 | $0 | 5,914,572 (Indirect) |
View |
Ownership |
2025-06-23 6:24 pm |
N/A 2035-04-14 |
GLYCOMIMETICS INC | CBIO | Lubner David Charles Director |
0 | $0 | 20,164 (Direct) |
View |
Ownership |
2025-06-23 6:23 pm |
N/A N/A |
GLYCOMIMETICS INC | CBIO | Violin Jonathan Director |
0 | $0 | 296,301 (Direct) |
View |
Ownership |
2025-06-23 6:23 pm |
N/A 2034-12-11 |
GLYCOMIMETICS INC | CBIO | Balcom Alexandra Director |
0 | $0 | 20,164 (Direct) |
View |
Ownership |
2025-06-23 6:22 pm |
N/A 2034-12-11 |
GLYCOMIMETICS INC | CBIO | Moran Susan Director |
0 | $0 | 20,164 (Direct) |
View |
| 2025-06-13 Other |
2025-06-17 6:53 pm |
N/A N/A |
GLYCOMIMETICS INC | CBIO | BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC LAMPERT MARK N 10% Owner |
1,857,561 | $0 | 1,919,944 (Direct) |
View |
Ownership |
2024-07-29 5:55 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | Siren L.L.C. Invus Global Management LLC DEBBANE RAYMOND 10% Owner |
0 | $0 | 8,589,064 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-01 4:30 pm |
N/A 2034-04-30 |
GLYCOMIMETICS INC | GLYC | Koenig Scott Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-01 4:30 pm |
N/A 2034-04-30 |
GLYCOMIMETICS INC | GLYC | Goldberg Mark Alan Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-01 4:29 pm |
N/A 2034-04-30 |
GLYCOMIMETICS INC | GLYC | PEARSON TIMOTHY R Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-01 4:27 pm |
N/A 2034-04-30 |
GLYCOMIMETICS INC | GLYC | King Rachel K. Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-01 4:26 pm |
N/A 2034-04-30 |
GLYCOMIMETICS INC | GLYC | Andrews Patricia S Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-01 4:25 pm |
N/A 2034-04-30 |
GLYCOMIMETICS INC | GLYC | Jackson Scott Thomas Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-01 4:24 pm |
N/A 2034-04-30 |
GLYCOMIMETICS INC | GLYC | JUNIUS DANIEL M Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-03-29 Option Award |
2024-04-02 4:05 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | JUNIUS DANIEL M Director |
5,209 | $3 | 98,459 (Direct) |
View |
| 2024-03-29 Option Award |
2024-04-02 4:05 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | King Rachel K. Director |
3,334 | $3 | 659,095 (Direct) |
View |
| 2024-03-29 Option Award |
2024-04-02 4:05 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | Goldberg Mark Alan Director |
4,584 | $3 | 36,325 (Direct) |
View |
| 2024-01-12 Option Award |
2024-01-17 4:05 pm |
N/A 2034-01-11 |
GLYCOMIMETICS INC | GLYC | Johnson Bruce S SVP & Chief Commercial Officer |
250,000 | $0 | 250,000 (Direct) |
View |
| 2024-01-12 Option Award |
2024-01-17 4:05 pm |
N/A 2034-01-11 |
GLYCOMIMETICS INC | GLYC | Semerjian Harout Chief Executive Officer |
695,000 | $0 | 695,000 (Direct) |
View |
| 2024-01-12 Option Award |
2024-01-17 4:05 pm |
N/A 2034-01-11 |
GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer |
250,000 | $0 | 250,000 (Direct) |
View |